Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_assertion type Assertion NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_head.
- NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_assertion description "[In a pilot study of long-term treatment, 42 such patients were randomly assigned to 6 million units of interferon alfa 2b (IFN-alpha2b) three times per week for 24 consecutive months (n = 21, 4 with cirrhosis) or to no therapy (n = 21, 3 with cirrhosis).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_provenance.
- NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_assertion evidence source_evidence_literature NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_provenance.
- NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_assertion SIO_000772 9398007 NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_provenance.
- NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_assertion wasDerivedFrom befree-2016 NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_provenance.
- NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_assertion wasGeneratedBy ECO_0000203 NP1385242.RANmhMGbaxXBoV6ZkKwwvQs5bMl5c9ub_Dsg3RbyH63FU130_provenance.